CLAIMS

We claim:

1. A compound of formula (**I**):



I

or a pharmaceutically acceptable salt thereof, wherein

R^1 and R^2 are independently chosen from C_{1-12}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, C_{7-12}spirocycloalkyl-C_{1-4}alkylene, bridged C_{5-10}bicycloalkyl, bridged C_{5-10}bicycloalkyl-C_{1-4}alkylene, fused C_{5-10}bicycloalkyl, C_{10-16}dispirocycloalkyl, C_{10-16}dispirocycloalkyl-C_{1-4}alkylene, bridged C_{9-12}tricycloalkyl, bridged C_{9-12}tricycloalkyl-C_{1-4}alkylene, C_{3-7}cycloalkyl-C_{3-7}cycloalkylene, and 5- to 7-membered monocyclic heterocyclyl having from 1 to 3 heteroatoms chosen from N, O, and S, wherein each C_{1-12}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a;

R^3, R^4, R^5, and R^6 are independently chosen from C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene, wherein each C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene is optionally substituted with from one to three R^b; or optionally:

R^3 and R^4 together with the carbon atom to which they are attached form a 3- to 6- membered saturated or partially unsaturated carbocyclic ring optionally substituted with from one to three R^b; and R^5 and R^6 are independently chosen from C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene, wherein each C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene is optionally substituted with from one to three R^b; or

R^3 and R^4 are independently chosen from C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene, wherein each C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene is optionally substituted with from one to three R^b; and R^5 and R^6 together with the carbon atom to which they are attached form a 3- to 6- membered

saturated or partially unsaturated carbocyclic ring optionally substituted with from one to three R^b; or

R^3 and R^4 together with the carbon atom to which they are attached form a 3- to 6- membered saturated or partially unsaturated carbocyclic ring optionally substituted with from one to three R^b; and R^5 and R^6 together with the carbon atom to which they are attached form a 3- to 6- membered saturated or partially unsaturated carbocyclic ring optionally substituted with from one to three R^b;

B is  or ;

R^7 is hydrogen or R^8;

R^8 is $–L^1–(L^2)_m–(L^3)_n–R^{8a}$;

L^1 is chosen from a bond, –C(O)–, and –C(O)O–;

L^2 is $C_{1\text{-}6}$alkylene;

L^3 is –C(O)O– or ;

R^{8a} is chosen from $C_{1\text{-}12}$alkyl, aryl, –C(O)–aryl, –C(O)–$C_{1\text{-}4}$alkyl, –S–C(O)–$C_{1\text{-}4}$alkyl, , , , , and , wherein aryl and –C(O)–aryl are optionally substituted with one or two R^c;

each R^a is independently chosen from $C_{1\text{-}4}$alkyl, halo, $C_{1\text{-}4}$haloalkyl, and –O–$C_{1\text{-}4}$alkyl;

each R^b is independently $C_{1\text{-}4}$alkyl;

each R^c is independently $C_{1\text{-}4}$alkyl or –OC(O)–$C_{1\text{-}4}$alkyl;

m and n are independently 0 or 1; and

p is 0, 1, or 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are independently chosen from $C_{1\text{-}8}$alkyl, aryl-$C_{1\text{-}4}$alkylene, $C_{3\text{-}7}$cycloalkyl, $C_{3\text{-}7}$cycloalkyl-$C_{1\text{-}4}$alkylene, aryl-$C_{3\text{-}7}$cycloalkylene, $C_{7\text{-}12}$spirocycloalkyl, $C_{7\text{-}12}$spirocycloalkyl-$C_{1\text{-}4}$alkylene, bridged $C_{5\text{-}10}$bicycloalkyl, bridged $C_{5\text{-}10}$bicycloalkyl-$C_{1\text{-}4}$alkylene, fused $C_{5\text{-}10}$bicycloalkyl, $C_{10\text{-}16}$dispirocycloalkyl, $C_{10\text{-}16}$dispirocycloalkyl-$C_{1\text{-}4}$alkylene, bridged $C_{9\text{-}12}$tricycloalkyl, bridged $C_{9\text{-}}$

$_{12}$tricycloalkyl-C_{1-4}alkylene, C_{3-7}cycloalkyl-C_{3-7}cycloalkylene, and 5- to 7-membered monocyclic heterocyclyl having from 1 to 3 heteroatoms chosen from N, O, and S, wherein each C_{1-8}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are independently chosen from C_{1-8}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, C_{7-12}spirocycloalkyl-C_{1-4}alkylene, bridged C_{5-10}bicycloalkyl-C_{1-4}alkylene, fused C_{5-10}bicycloalkyl, C_{10-16}dispirocycloalkyl-C_{1-4}alkylene, bridged C_{9-12}tricycloalkyl-C_{1-4}alkylene, C_{3-7}cycloalkyl-C_{3-7}cycloalkylene, and 5- to 7-membered monocyclic heterocyclyl having from 1 to 3 heteroatoms chosen from N, O, and S, wherein each C_{1-8}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are independently chosen from C_{1-8}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, C_{7-12}spirocycloalkyl, C_{7-12}spirocycloalkyl-C_{1-4}alkylene, and bridged C_{5-10}bicycloalkyl-C_{1-4}alkylene, wherein each C_{1-8}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are independently chosen from C_{5-8}alkyl, C_{5-7}cycloalkyl, C_{5-7}cycloalkyl-C_{1-4}alkylene, C_{7-9}spirocycloalkyl, C_{7-9}spirocycloalkyl-C_{1-4}alkylene, and bridged C_{5-7}bicycloalkyl-C_{1-4}alkylene, wherein each C_{5-8}alkyl, C_{5-7}cycloalkyl, C_{5-7}cycloalkyl-C_{1-4}alkylene, C_{7-9}spirocycloalkyl, C_{7-9}spirocycloalkyl-C_{1-4}alkylene, and bridged C_{5-7}bicycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are different.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are the same.

8. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are the same and chosen from C_{1-8}alkyl, aryl-C_{1-4}alkylene, C_{3-7}cycloalkyl, C_{3-}

$_{7}$cycloalkyl-C_{1-4}alkylene, aryl-C_{3-7}cycloalkylene, C_{7-12}spirocycloalkyl, C_{7-12}spirocycloalkyl-C_{1-4}alkylene, bridged C_{5-10}bicycloalkyl-C_{1-4}alkylene, fused C_{5-10}bicycloalkyl, C_{10-16}dispirocycloalkyl-C_{1-4}alkylene, bridged C_{9-12}tricycloalkyl-C_{1-4}alkylene, C_{3-7}cycloalkyl-C_{3-7}cycloalkylene, and 5- to 7-membered monocyclic heterocyclyl having from 1 to 3 heteroatoms chosen from N, O, and S, wherein each C_{1-8}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

9. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are the same and chosen from C_{1-8}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, C_{7-12}spirocycloalkyl, C_{7-12}spirocycloalkyl-C_{1-4}alkylene, and bridged C_{5-10}bicycloalkyl-C_{1-4}alkylene, wherein each C_{1-8}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkyl-C_{1-4}alkylene, C_{7-12}spirocycloalkyl, and C_{7-12}spirocycloalkyl-C_{1-4}alkylene is optionally substituted with from one to three R^a.

10. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are independently chosen from 



11. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are the same and chosen from



12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^3, R^4, R^5, and R^6 are each independently chosen from methyl, ethyl, cyclopropyl, and benzyl, wherein each methyl, ethyl, cyclopropyl, and benzyl is optionally substituted with from one to three R^b.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^5 are the same.

14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^5 are both methyl.

15. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^4 and R^6 are the same.

16. The compound of any one of claims 1-12 and 15, or a pharmaceutically acceptable salt thereof, wherein R^4 and R^6 are both ethyl or both benzyl.

17. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are the same.

18. The compound of any one of claims 1-12 and 17, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are both methyl.

19. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are the same.

20. The compound of any one of claims 1-12 and 19, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are both methyl.

21. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 together with the carbon atom to which they are attached form a cyclopropane ring or a cyclobutane ring, wherein the cyclopropane ring or the cyclobutane ring is optionally substituted with from one to three R^b; and R^5 and R^6 are independently chosen from $C_{1\text{-}4}$alkyl, $C_{3\text{-}6}$cycloalkyl, and aryl-$C_{1\text{-}4}$alkylene, wherein each $C_{1\text{-}4}$alkyl, $C_{3\text{-}6}$cycloalkyl, and aryl-$C_{1\text{-}4}$alkylene is optionally substituted with from one to three R^b.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^6 are independently chosen from methyl, ethyl, cyclopropyl, and benzyl, wherein each methyl, ethyl, cyclopropyl, and benzyl is optionally substituted with from one to three R^b.

23. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are independently chosen from C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene, wherein each C_{1-4}alkyl, C_{3-6}cycloalkyl, and aryl-C_{1-4}alkylene is optionally substituted with from one to three R^b; and R^5 and R^6 together with the carbon atom to which they are attached form a cyclopropane ring or a cyclobutane ring, wherein the cyclopropane ring or the cyclobutane ring is optionally substituted with from one to three R^b.

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are independently chosen from methyl, ethyl, cyclopropyl, and benzyl, wherein each methyl, ethyl, cyclopropyl, and benzyl is optionally substituted with from one to three R^b.

25. The compound any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 together with the carbon atom to which they are attached form a cyclopropane ring or a cyclobutane ring, wherein the cyclopropane ring or the cyclobutane ring is optionally substituted with from one to three R^b; and R^5 and R^6 together with the carbon atom to which they are attached form a cyclopropane ring or a cyclobutane ring, wherein the cyclopropane ring or the cyclobutane ring is optionally substituted with from one to three R^b.

26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein each R^b is independently methyl or ethyl.

27. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R^3, R^4, R^5, and R^6 are the same.

28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R^3, R^4, R^5, and R^6 are each methyl or cyclopropyl.

29. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R^3, R^4, R^5, and R^6 are each methyl.

30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt thereof, having the formula (**II**):



.

II

31. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt thereof, having the formula (**III**):



III

32. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, having the formula (**IV**):



IV

33. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, having the formula (**V**):



V

34. The compound of claim 1, wherein the compound is chosen from:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



or a pharmaceutically acceptable salt thereof.

35. The compound of claim 1, wherein the compound is chosen from:

, , , , , , or 

or a pharmaceutically acceptable salt thereof.

36. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

37. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

38. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

39. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

40. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

41. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

42. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

43. The compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

44. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

45. The pharmaceutical composition of claim 44, further comprising one, two, three, or four additional therapeutic agents.

46. The pharmaceutical composition of claim 45, wherein the additional therapeutic agent or agents are anti-HIV agents.

47. The pharmaceutical composition of claim 45 or 46, wherein the additional therapeutic agent or agents are chosen from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, Nef inhibitors, latency reversing agents, HIV

bNAbs, agonists of TLR7, TLR8, and TLR9, HIV vaccines, cytokines, immune checkpoint inhibitors, FLT3 ligands, T cell and NK cell recruiting bispecific antibodies, chimeric T cell receptors targeting HIV antigens, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

48. The pharmaceutical composition of any one of claims 45-47, wherein the additional therapeutic agent or agents are chosen from dolutegravir, cabotegravir, islatravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and combinations thereof.

49. The pharmaceutical composition of any one of claims 44-48, wherein the pharmaceutical composition is for parenteral administration.

50. Use of a compound of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 44-49, in the manufacture of a medicament for treating an HIV infection.

51. The use of claim 50, wherein the medicament is to be administered in combination with one, two, three, or four additional therapeutic agents.

52. The use of claim 51, wherein the additional therapeutic agent or agents are anti-HIV agents.

53. The use of claim 51 or 52, wherein the additional therapeutic agent or agents are chosen from HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV capsid inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, Nef inhibitors, latency reversing agents, HIV bNAbs, agonists of TLR7, TLR8, and TLR9, HIV vaccines, cytokines, immune checkpoint inhibitors, FLT3 ligands, T cell and NK cell recruiting bispecific antibodies, chimeric T cell receptors targeting HIV antigens, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

54. The use of any one of claims 51-53, wherein the additional therapeutic agent or agents are chosen from dolutegravir, cabotegravir, islatravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and combinations thereof.

55. The use of any one of claims 50-54, wherein the medicament is to be administered intravenously, subcutaneously, or intramuscularly.